Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Get Free Report) Director Peter Ashley Marks bought 47,620 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The stock was bought at an average price of $0.50 per share, with a total value of $23,810.00. Following the acquisition, the director directly owned 191,340 shares in the company, valued at $95,670. The trade was a 33.13% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
Alterity Therapeutics Price Performance
Shares of NASDAQ ATHE opened at $4.50 on Thursday. The business’s 50 day moving average is $4.76 and its two-hundred day moving average is $4.32. Alterity Therapeutics Limited – Sponsored ADR has a 52-week low of $2.66 and a 52-week high of $5.89.
Alterity Therapeutics (NASDAQ:ATHE – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.28) EPS for the quarter. The firm had revenue of $0.31 million during the quarter. Sell-side analysts expect that Alterity Therapeutics Limited – Sponsored ADR will post -0.12 EPS for the current fiscal year.
Institutional Trading of Alterity Therapeutics
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on ATHE shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Friday, July 17th. UBS Group set a $12.00 price objective on shares of Alterity Therapeutics in a report on Tuesday, August 11th. Craig Hallum set a $2.00 target price on shares of Alterity Therapeutics in a research note on Tuesday, August 11th. LADENBURG THALM/SH SH initiated coverage on shares of Alterity Therapeutics in a report on Tuesday, June 16th. They set a “buy” rating and a $10.00 target price on the stock. Finally, JonesTrading started coverage on shares of Alterity Therapeutics in a research report on Tuesday, June 30th. They issued a “buy” rating and a $16.00 price target for the company. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.
Read Our Latest Research Report on Alterity Therapeutics
About Alterity Therapeutics
Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.
Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.
Read More
- Five stocks we like better than Alterity Therapeutics
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
